Key Takeaways
- Sector: Healthcare, Healthtech & Medtech, Business Services.
- Geography: United States, Australia, New Zealand.
Analysis
Premier Biotech, a prominent player in drug and alcohol testing solutions backed by Align Capital Partners (ACP), has significantly expanded its market reach and product offerings through the strategic acquisitions of NexScreen and TransMed. This dual transaction marks a pivotal moment for Premier Biotech, enhancing its capabilities in point-of-care diagnostics and e-commerce-driven supply chains.
The integration of NexScreen, a provider of diagnostic testing solutions with a strong presence in the United States, Australia, and New Zealand, extends Premier Biotech's international footprint. Simultaneously, TransMed brings a robust e-commerce platform and an extensive catalog of drug testing products and laboratory supplies, serving over 1,000 direct clients. This acquisition deepens Premier Biotech's engagement with key sectors including healthcare, government, and workplace safety.
This move aligns with the broader trend in the diagnostics sector, which is experiencing sustained growth driven by increasing demand for rapid and accurate testing. The global in vitro diagnostics market, for instance, is projected to reach hundreds of billions of dollars in the coming years, fueled by advancements in technology and a growing emphasis on preventative healthcare. Premier Biotech's strategic acquisitions position it to capitalize on this expanding market.
“These acquisitions represent another step forward in our growth strategy,” stated Matt Michalik, CEO of Premier Biotech. “NexScreen expands our presence in Australia and New Zealand, while deepening our core markets. TransMed’s broad product catalog, strong e-commerce platform, strategic vendor relationships and customer-first approach make it a strong strategic and cultural fit. We believe these partnerships will deliver meaningful benefits to our customers and our business.”
The leadership of the acquired companies expressed enthusiasm for the integration. John Debrovner, CEO of NexScreen, commented, “Partnering with Premier Biotech is an exciting next step for NexScreen, and we look forward to bringing Premier’s full solution set to our customers. Premier’s robust portfolio is unmatched, and we are thrilled to offer their oral fluid, laboratory and technology solutions to our markets.” Ted Bernhardt, owner of TransMed, added, “Since 2008, we’ve built our reputation as a trusted partner by offering a wide variety of high-quality solutions at competitive prices. Teaming up with Premier enables us to deliver even greater innovation, expanded offerings and enhanced support to our customers.”
This is the seventh acquisition Premier Biotech has completed since its partnership with Align Capital Partners commenced in November 2022. The private equity firm, known for its focus on the lower-middle market, has actively supported Premier Biotech's expansion strategy, aiming to build a comprehensive, end-to-end suite of diagnostic solutions. The ACP deal team included Rob Langley, Ervin Cash, Matt Bowen, and Sarah Mahosky.
The combined entity is now better equipped to offer a holistic range of testing products and services, from point-of-care devices to laboratory analysis and supply chain management. This consolidation is expected to enhance operational efficiencies and customer service, solidifying Premier Biotech's competitive position in the global diagnostics market.